InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Global X S&P Biotech ETF (CURE)
  6. Company Announcements

Global X S&P Biotech ETF (ASX: CURE) - Announcements

- Current share price for CURE : $43.920

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$30 Global X Units on Issue December 2022 4 Jan 2023 11:44AM $41.800 $43.920 risen by 5.07%
$30 Global X Units on Issue November 2022 1 Dec 2022 3:49PM $42.220 $43.920 risen by 4.03%
$30 Global X Units on Issue October 2022 7 Nov 2022 5:28PM $42.520 $43.920 risen by 3.29%
$30 PDS dated 25 October 2022 26 Oct 2022 1:28PM $43.300 $43.920 risen by 1.43%
$30 Global X Units on Issue September 2022 4 Oct 2022 4:22PM $42.570 $43.920 risen by 3.17%
$30 CURE Annual Financial Report 29 Sep 2022 1:21PM $42.640 $43.920 risen by 3%
$30 Change of Company Name 16 Sep 2022 2:04PM $43.560 $43.920 risen by 0.83%
$30 Replacement PDS dated 16 September 2022 16 Sep 2022 1:37PM $43.560 $43.920 risen by 0.83%
$30 ETFS Units on Issue August 2022 5 Sep 2022 12:35PM $42.320 $43.920 risen by 3.78%
$30 ETFS Units on Issue July 2022 2 Aug 2022 6:59PM $38.700 $43.920 risen by 13.49%
$30 Update - Dividend/Distribution 1 Jul 2022 6:50PM $36.530 $43.920 risen by 20.23%
$30 ETFS Units on Issue June 2022 1 Jul 2022 6:01PM $36.530 $43.920 risen by 20.23%
$30 Updated Estimated Distribution Announcement - Jun 2022 30 Jun 2022 9:52AM $36.920 $43.920 risen by 18.96%
$30 Estimated Distribution Announcement - June 2022 24 Jun 2022 5:11PM $38.030 $43.920 risen by 15.49%
$30 Change of ownership and control of responsible entity 15 Jun 2022 12:21PM $31.680 $43.920 risen by 38.64%
$30 ETFS Units on Issue May 2022 3 Jun 2022 11:34AM $32.400 $43.920 risen by 35.56%
$30 Replacement PDS dated 9 May 2022 9 May 2022 8:49AM $35.680 $43.920 risen by 23.09%
$30 ETFS Units on Issue April 2022 2 May 2022 6:01PM $36.200 $43.920 risen by 21.33%
$30 ETFS Units on Issue March 2022 1 Apr 2022 4:15PM $41.350 $43.920 risen by 6.22%
$30 CURE Half Year Accounts 16 Mar 2022 8:51AM $38.990 $43.920 risen by 12.64%
$30 ETFS Units on Issue February 2022 1 Mar 2022 10:26AM $42.240 $43.920 risen by 3.98%
$30 ETFS Units on Issue January 2022 1 Feb 2022 5:01PM $45.580 $43.920 fallen by 3.64%
$30 ETFS Units on Issue December 2021 5 Jan 2022 8:34AM $55.190 $43.920 fallen by 20.42%
$30 ETFS Units on Issue November 2021 1 Dec 2021 7:54PM $56.410 $43.920 fallen by 22.14%
$30 ETFS Units on Issue October 2021 2 Nov 2021 11:06AM $59.000 $43.920 fallen by 25.56%

51 - 75 of 110 results

Page 3 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.